The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy

Hoon Chul Kang, Baik-Lin Eun, Chang Wu Lee, Han Ku Moon, Joon Sik Kim, Dong Wook Kim, Joon Soo Lee, Kyu Young Chae, Byung Ho Cha, Eun Sook Suh, Jung Chae Park, Kyunghwa Lim, Eun Hye Ha, Dong Ho Song, Heung Dong Kim

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Methods: A multicenter, randomized, open-label, observer-blinded, parallel-group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment. Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM. Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.

Original languageEnglish
Pages (from-to)1716-1723
Number of pages8
JournalEpilepsia
Volume48
Issue number9
DOIs
Publication statusPublished - 2007 Sep 1

Fingerprint

Rolandic Epilepsy
Carbamazepine
Cognition
Neuropsychological Tests
Problem Behavior
topiramate
Clinical Trials
Therapeutics

Keywords

  • Behavioral problems
  • Benign rolandic epilepsy
  • Carbamazepine
  • Cognitive function
  • Topiramate

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. / Kang, Hoon Chul; Eun, Baik-Lin; Wu Lee, Chang; Ku Moon, Han; Kim, Joon Sik; Wook Kim, Dong; Soo Lee, Joon; Young Chae, Kyu; Ho Cha, Byung; Sook Suh, Eun; Chae Park, Jung; Lim, Kyunghwa; Hye Ha, Eun; Ho Song, Dong; Dong Kim, Heung.

In: Epilepsia, Vol. 48, No. 9, 01.09.2007, p. 1716-1723.

Research output: Contribution to journalArticle

Kang, HC, Eun, B-L, Wu Lee, C, Ku Moon, H, Kim, JS, Wook Kim, D, Soo Lee, J, Young Chae, K, Ho Cha, B, Sook Suh, E, Chae Park, J, Lim, K, Hye Ha, E, Ho Song, D & Dong Kim, H 2007, 'The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy', Epilepsia, vol. 48, no. 9, pp. 1716-1723. https://doi.org/10.1111/j.1528-1167.2007.01160.x
Kang, Hoon Chul ; Eun, Baik-Lin ; Wu Lee, Chang ; Ku Moon, Han ; Kim, Joon Sik ; Wook Kim, Dong ; Soo Lee, Joon ; Young Chae, Kyu ; Ho Cha, Byung ; Sook Suh, Eun ; Chae Park, Jung ; Lim, Kyunghwa ; Hye Ha, Eun ; Ho Song, Dong ; Dong Kim, Heung. / The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. In: Epilepsia. 2007 ; Vol. 48, No. 9. pp. 1716-1723.
@article{c06394c622a34fd4a2fb0ca4167098e9,
title = "The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy",
abstract = "Methods: A multicenter, randomized, open-label, observer-blinded, parallel-group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment. Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM. Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.",
keywords = "Behavioral problems, Benign rolandic epilepsy, Carbamazepine, Cognitive function, Topiramate",
author = "Kang, {Hoon Chul} and Baik-Lin Eun and {Wu Lee}, Chang and {Ku Moon}, Han and Kim, {Joon Sik} and {Wook Kim}, Dong and {Soo Lee}, Joon and {Young Chae}, Kyu and {Ho Cha}, Byung and {Sook Suh}, Eun and {Chae Park}, Jung and Kyunghwa Lim and {Hye Ha}, Eun and {Ho Song}, Dong and {Dong Kim}, Heung",
year = "2007",
month = "9",
day = "1",
doi = "10.1111/j.1528-1167.2007.01160.x",
language = "English",
volume = "48",
pages = "1716--1723",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy

AU - Kang, Hoon Chul

AU - Eun, Baik-Lin

AU - Wu Lee, Chang

AU - Ku Moon, Han

AU - Kim, Joon Sik

AU - Wook Kim, Dong

AU - Soo Lee, Joon

AU - Young Chae, Kyu

AU - Ho Cha, Byung

AU - Sook Suh, Eun

AU - Chae Park, Jung

AU - Lim, Kyunghwa

AU - Hye Ha, Eun

AU - Ho Song, Dong

AU - Dong Kim, Heung

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Methods: A multicenter, randomized, open-label, observer-blinded, parallel-group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment. Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM. Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.

AB - Methods: A multicenter, randomized, open-label, observer-blinded, parallel-group clinical trial was conducted. TPM was introduced at a dose of 12.5 mg/day with the minimum target dose of 50 mg/day in patients <30 kg and 75 mg/day in patients >30 kg over 4 weeks. CBZ was started at a dose of 10 mg/kg/day with the minimum target dose of 20 mg/kg/day over 4 weeks. Additional individual escalation was allowed up to a maximum target dose. The primary study end point was change on a neuropsychological test battery after 28 weeks of treatment. Results: Neuropsychological data were available for 88 patients (45 patients for TPM and 43 patients for CBZ). Of the cognitive variables measured, arithmetic showed significant worsening in TPM (p = 0.037). An additional test, for maze, also showed a significantly greater improvement for CBZ (p = 0.026). Of behavioral variables, no significant changes were found but the scores had a negative trend for the TPM. When 30 patients on the minimum target dose for TPM were compared to 40 patients treated with minimum target CBZ, there was no significant worsening of cognitive and behavioral effects in the TPM. Conclusion: The pattern of neuropsychometric changes with TPM seemed to be slightly worse overall than CBZ. However, outcome with the minimum target dose did not differ significantly in comparisons between the treatment groups.

KW - Behavioral problems

KW - Benign rolandic epilepsy

KW - Carbamazepine

KW - Cognitive function

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=34548432277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548432277&partnerID=8YFLogxK

U2 - 10.1111/j.1528-1167.2007.01160.x

DO - 10.1111/j.1528-1167.2007.01160.x

M3 - Article

VL - 48

SP - 1716

EP - 1723

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 9

ER -